Diffuse-type tenosynovial giant cell tumour: Current treatment concepts and future perspectives


      • Although benign, diffuse-type tenosynovial giant cell tumour (D-TGCT) can cause significant pain and impaired quality of life.
      • Surgery is the mainstay of treatment for D-TGCT, yet relapse is common.
      • Current treatments include surgery, external beam radiotherapy, radiosynovectomy.
      • New therapeutic strategies include immunotherapy and targeted therapy.


      At present, the optimal treatment strategy in patients with diffuse-type tenosynovial giant cell tumour (D-TGCT) is unclear. The purpose of this review was to describe current treatment options, and to highlight recent developments in the knowledge of the molecular pathogenesis of D-TGCT as well as related therapeutic implications. Epidemiology, clinical features, and the pathogenesis of D-TGCT and the most widely used treatment modalities are described. D-TGCT is a benign clonal neoplastic proliferation arising from the synovium. Patients are often symptomatic and require multiple surgical procedures during their lifetime. Currently, surgery is the main treatment for patients with D-TGCT, with relapse rates ranging from 14% to 55%. Radiosynovectomy and external beam radiotherapy have been used in combination with surgical excision or as single modalities. The finding that D-TGCT cells overexpress colony-stimulating factor 1 (CSF1), resulting in recruitment of CSF1 receptor (CSF1R)-bearing macrophages that are polyclonal and make up the bulk of the tumour, has led to clinical trials with CSF1R inhibitors. These inhibitors include small molecules such as imatinib, nilotinib, PLX3397, and the monoclonal antibody RG7155. In conclusion, D-TGCT impairs patients’ quality of life significantly. The evidence that the pathogenetic loop of D-TGCT can be inhibited could potentially change the therapeutic armamentarium for this condition. Clinical trials of agents that target D-TGCT are currently ongoing. In the meantime, international registries should be activated in order to provide useful information on this relatively rare tumour.


      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to European Journal of Cancer
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Greenspan A.
        • Remagen W.
        Tumors and tumor-like lesions of the joints.
        in: Greenspan A. Remagen W. Differential diagnosis of tumors and tumor-like lesions of bones and joints. Lippincott-Raven Publishers, Philadelphia1998: 389-422
        • Mankin H.
        • Trahan C.
        • Hornicek F.
        Pigmented villonodular synovitis of joints.
        J Surg Oncol. 2011; 103: 386-389
        • O'Connell J.X.
        Pathology of the synovium.
        Am J Clin Pathol. 2000; 114: 773-784
        • Sciot R.
        • Rosai J.
        • Dal Cin P.
        • et al.
        Analysis of 35 cases of localized and diffuse tenosynovial giant cell tumor: a report from the chromosomes and morphology (CHAMP) study group.
        Genes Chromosomes Cancer. 1993; 6: 212-217
        • de Saint Aubain Somerhausen N.
        • van de Rijn M.
        Tenosynovial giant cell tumour, diffuse type.
        in: Fletcher C.D.M. Bridge J. Hogendoorn P. Mertens F. World Health Organization classification of tumours of soft tissue and bone. 4th ed. IARC Press, Lyon2013: 102-103
        • West R.B.
        • Rubin B.P.
        • Miller M.A.
        • et al.
        A landscape effect in tenosynovial giant-cell tumor from activation of CSF1 expression by a translocation in a minority of tumor cells.
        Proc Natl Acad Sci USA. 2006; 103: 690-695
        • Ottaviani S.
        • Ayral X.
        • Dougados M.
        • Gossec L.
        Pigmented villonodular synovitis: a retrospective single-center study of 122 cases and review of the literature.
        Semin Arthritis Rheum. 2011; 40: 539-546
        • Schwartz H.S.
        • Unni K.K.
        • Pritchard D.J.
        Pigmented villonodular synovitis.
        Clin Orthop Relat Res. 1989 Oct; : 243-255
        • Palmerini E.
        • Staals E.L.
        • Maki R.G.
        • et al.
        Tenosynovial giant cell tumour/pigmented villonodular synovitis: outcome of 294 patients before the era of kinase inhibitors.
        Eur J Cancer. 2015; 51: 210-217
        • Heyd R.
        • Micke O.
        • Berger B.
        • Eich H.T.
        • Ackermann H.
        • Seegenschmiedt M.H.
        Radiation therapy for treatment of pigmented villonodular synovitis: results of a national patterns of care study.
        Int J Radiat Oncol Biol Phys. 2010; 78: 199-204
        • Mollon B.
        • Lee A.
        • Busse J.W.
        • et al.
        The effect of surgical synovectomy and radiotherapy on the rate of recurrence of pigmented villonodular synovitis of the knee: an individual patient meta-analysis.
        Bone Joint J. 2015; 97-B: 550-557
        • Cassier P.A.
        • Italiano A.
        • Gomez-Roca C.A.
        • et al.
        CSF1R inhibition with emactuzumab in locally advanced diffuse-type tenosynovial giant cell tumours of the soft tissue: a dose-escalation and dose-expansion phase 1 study.
        Lancet Oncol. 2015; 16: 949-956
        • Gelderblom H.
        • Pérol D.
        • Chevreau C.
        • et al.
        An open-label international multicentric phase II study of nilotinib in progressive pigmented villo-nodular synovitis (PVNS) not amenable to a conservative surgical treatment.
        J Clin Oncol. 2013; 31 (abstr 10516)
        • Tap W.D.
        • Wainberg Z.A.
        • Anthony S.P.
        • et al.
        Structure-guided blockade of CSF1R kinase in tenosynovial giant-cell tumor.
        N Engl J Med. 2015; 373: 428-437
      1. NCT01643850. [accessed 09.07.15].

        • SEER (Surveillance, Epidemiology and End Results)
        Cancer statistics review, 1975–2010.
        National Cancer Institute, 2013
        • Dorwart R.H.
        • Genant H.K.
        • Johnston W.H.
        • Morris J.M.
        Pigmented villonodular synovitis of the shoulder: radiologic-pathologic assessment.
        AJR. 1984; 143: 886-888
        • Jelinek J.S.
        • Kransdorf M.J.
        • Shmookler B.M.
        • Aboulafia A.A.
        • Malawer M.M.
        Giant cell tumor of the tendon sheath: MR findings in nine cases.
        AJR. 1994; 162: 919-922
        • Granowitz S.P.
        • D'Antonio J.
        • Mankin H.L.
        The pathogenesis and long-term end results of pigmented villonodular synovitis.
        Clin Orthop Relat Res. 1976 Jan–Feb; : 335-351
        • van der Heijden L.
        • Gibbons C.L.
        • Hassan A.B.
        • et al.
        A multidisciplinary approach to giant cell tumors of tendon sheath and synovium–a critical appraisal of literature and treatment proposal.
        J Surg Oncol. 2013; 107: 433-445
        • Chiari C.
        • Pirich C.
        • Brannath W.
        • Kotz R.
        • Trieb K.
        What affects the recurrence and clinical outcome of pigmented villonodular synovitis?.
        Clin Orthop Relat Res. 2006; 450: 172-178
        • Chin K.R.
        • Brick G.W.
        Extraarticular pigmented villonodular synovitis.
        Clin Orthop Relat Res. 2002; 404: 330-338
        • Ogilvie-Harris D.J.
        • McLean J.
        • Zarnett M.E.
        Pigmented villonodular synovitis of the knee. The results of total arthroscopic synovectomy, partial, arthroscopic synovectomy, and arthroscopic local excision.
        J Bone Joint Surg Am. 1992; 74: 119-123
        • De Ponti A.
        • Sansone V.
        • Malchere M.
        Result of arthroscopic treatment of pigmented villonodular synovitis of the knee.
        Arthroscopy. 2003; 19: 602-607
        • de Visser E.
        • Veth R.P.H.
        • Pruszczynski M.
        • Wobbes T.
        • Van de Putte L.B.
        Diffuse and localized pigmented villonodular synovitis: evaluation of treatment of 38 patients.
        Arch Orthop Trauma Surg. 1999; 119: 401-404
        • Sharma V.
        • Cheng E.Y.
        Outcomes after excision of pigmented villonodular synovitis of the knee.
        Clin Orthop Relat Res. 2009; 467: 2852-2858
        • Colman M.W.
        • Ye J.
        • Weiss K.R.
        • Goodman M.A.
        • McGough 3rd, R.L.
        Does combined open and arthroscopic synovectomy for diffuse PVNS of the knee improve recurrence rates?.
        Clin Orthop Relat Res. 2013; 471: 883-890
        • Flandry F.C.
        • Hughston J.C.
        • Jacobson K.E.
        • Barrack R.L.
        • McCann S.B.
        • Kurtz D.M.
        Surgical treatment of diffuse pigmented villonodular synovitis of the knee.
        Clin Orthop Relat Res. 1994 Mar; : 183-192
        • Martin R.C.
        • Osborne D.L.
        • Edwards M.J.
        • Wrightson W.
        • McMasters K.M.
        Giant cell tumor of tendon sheath, tenosynovial giant cell tumor, and pigmented villonodular synovitis: defining the presentation, surgical therapy and recurrence.
        Oncol Rep. 2000; 7: 413-419
        • Schwartz H.S.
        • Unni K.K.
        • Pritchard D.J.
        Pigmented villonodular synovitis. A retrospective review of affected large joints.
        Clin Orthop Relat Res. 1989 Oct; : 243-255
        • Flipo R.M.
        • Desvigne-Noulet M.C.
        • Cotten A.
        • et al.
        Pigmented villonodular synovitis of the hip. Results of a national survey apropos of 58 cases.
        Rev Rhum Ed Fr. 1994; 61: 85-95
        • Hamlin B.R.
        • Duffy G.P.
        • Trousdale R.T.
        • Morrey B.F.
        Total knee arthroplasty in patients who have pigmented villonodular synovitis.
        J Bone Joint Surg Am. 1998; 80: 76-82
        • Berger B.
        • Ganswindt U.
        • Bamberg M.
        • Hehr T.
        External beam radiotherapy as postoperative treatment of diffuse pigmented villonodular synovitis.
        Int J Radiat Oncol Biol Phys. 2007; 67: 1130-1134
        • Blanco C.E.R.
        • Leon H.O.
        • Guthrie T.B.
        Combined partial arthroscopic synovectomy and radiation therapy for diffuse pigmented villonodular synovitis of the knee.
        Arthroscopy. 2001; 17: 527-531
        • Nassar W.A.M.
        • Bassiony A.A.
        • Elghazaly H.A.
        Treatment of diffuse pigmented villonodular synovitis of the knee with combined surgical and radiosynovectomy.
        HSS J. 2009; 5: 19-23
        • O'Sullivan B.
        • Cummings B.
        • Catton C.
        • et al.
        Outcome following radiation treatment for high-risk pigmented villonodular synovitis.
        Int J Radiat Oncol Biol Phys. 1995/06; 32: 777-786
        • Byers P.D.
        • Cotton R.E.
        • Deacon O.W.
        • et al.
        The diagnosis and treatment of pigmented villonodular synovitis.
        The J Bone Joint Surg Br. 1968; 50: 290-305
        • Bickels J.
        Unacceptable complications following intraintra-articular injection of yttrium 90 in the ankle joint for diffuse pigmented villonodular synovitis.
        J Bone Joint Surg Am. 2008; 90: 326
        • Jahangier Z.N.
        Pretreatment macrophage infiltration of the synovium predicts the clinical effect of both radiation synovectomy and intra-articular glucocorticoids.
        Ann Rheum Dis. 2006; 65: 1286-1292
        • Kampen W.U.
        • Voth M.
        • Pinkert J.
        • Krause A.
        Therapeutic status of radiosynoviorthesis of the knee with yttrium [90Y] colloid in rheumatoid arthritis and related indications.
        Rheumatology. 2007; 46: 16-24
        • Kisielinski K.
        • Bremer D.
        • Knutsen A.
        • Röttger P.
        • Fitzek J.G.
        Complications following radiosynoviorthesis in osteoarthritis and arthroplasty: osteonecrosis and intra-articular infection.
        Joint Bone Spine. 2010; 77: 252-257
        • O'Keefe R.J.
        • Rosier R.N.
        • Teot L.A.
        • Stewart J.M.
        • Hicks D.G.
        Cytokine and matrix metalloproteinase expression in pigmented villonodular synovitis may mediate bone and cartilage destruction.
        Iowa Orthop J. 1998; 18: 26-34
        • Kroot E.J.A.
        Tumour necrosis factor blockade in treatment resistant pigmented villonodular synovitis.
        Ann Rheum Dis. 2004; 64: 497-499
        • Kobak S.
        Intraarticular adalimumab in a patient with pigmented villonodular synovitis.
        Rheumatol Int. 2011; 31: 251-254
        • Fiocco U.
        • Sfriso P.
        • Oliviero F.
        • et al.
        Intra-articular treatment with the TNF-alpha antagonist, etanercept, in severe diffuse pigmented villonodular synovitis of the knee.
        Reumatismo. 2006; 58: 268-274
        • Dal Cin P.
        • Sciot R.
        • Samson I.
        • et al.
        Cytogenetic characterization of tenosynovial giant cell tumors (nodular tenosynovitis).
        Cancer Res. 1994; 54: 3986-3987
        • Cupp J.S.
        • Miller M.A.
        • Montgomery K.D.
        • et al.
        Translocation and expression of CSF1 in pigmented villonodular synovitis, tenosynovial giant cell tumor, rheumatoid arthritis and other reactive synovitides.
        Am J Surg Pathol. 2007; 31: 970-976
        • Möller E.
        • Mandahl N.
        • Mertens F.
        • Panagopoulos I.
        Molecular identification of COL6A3-CSF1 fusion transcripts in tenosynovial giant cell tumors.
        Genes Chromosomes Cancer. 2007; 47: 21-25
        • Blay J.Y.
        • El Sayadi H.
        • Thiesse P.
        • Garret J.
        • Ray-Coquard I.
        Complete response to imatinib in relapsing pigmented villonodular synovitis/tenosynovial giant cell tumor (PVNS/TGCT).
        Ann Oncol. 2007; 19: 821-822
        • Cassier P.A.
        • Gelderblom H.
        • Stacchiotti S.
        • et al.
        Efficacy of imatinib mesylate for the treatment of locally advanced and/or metastatic tenosynovial giant cell tumor/pigmented villonodular synovitis.
        Cancer. 2011; 118: 1649-1655
      2. NCT01207492. [accessed 23.07.15].

      3. Clinical NCT02371369. [accessed 18.09.15].

        • Ries C.H.
        • Cannarile M.A.
        • Hoves S.
        Targeting tumor-associated macrophages with anti-CSF-1R antibody reveals a strategy for cancer therapy.
        Cancer Cell. 2014; 25: 846-859
        • Cheng H.
        • Clarkson P.W.
        • Gao D.
        • Pacheco M.
        • Wang Y.
        • Nielsen T.O.
        Therapeutic antibodies targeting CSF1 impede macrophage recruitment in a xenograft model of tenosynovial giant cell tumor.
        Sarcoma. 2010; 2010: 174528